鉴定了6个与cuproptosis相关的基因,用于活性性结肠炎,具有诊断和治疗价值
Menglong Zou1,2, Wei Zhang1,2, Ying Zhu1
1The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Medicine
|October 31, 2023
概括
与cuproptosis相关的基因与活性性结肠炎 (UC) 有关. 六个关键基因 (ATOX1,SUMF1,MT1G,ATP7B,FDX1,LIAS) 被确定为活跃UC和潜在治疗标的生物标志物.
科学领域:
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 细胞亡是一种受调节的细胞死亡途径,与各种疾病有关.
- 性结肠炎 (UC) 是一种具有复杂病原性的慢性炎症性肠病.
- 了解cuproptosis在活性UC中的作用对于开发向疗法至关重要.
研究的目的:
- 调查与cuproptosis相关的基因与活性UC之间的关联.
- 确定关键的cuproptosis差异表达基因 (CuDEGs) 作为活跃UC的潜在生物标志物.
- 探索枢纽CuDEGs与免疫细胞透和活跃UC中的治疗反应之间的关系.
主要方法:
- 从基因表达综合 (GEO) 数据库中获得了活性UC的基因表达数据集.
- 鉴定了差异表达基因 (DEGs) 和cuproptosis差异表达基因 (CuDEGs).
- 利用机器学习算法来选枢纽CuDEG,并对独立数据集进行验证.
主要成果:
- 鉴定了27个CuDEG和六个基因特征 (ATOX1,SUMF1,MT1G,ATP7B,FDX1,LIAS) 与活性UC.强烈相关.
- 在活性UC中观察到不同的免疫细胞透模式,包括激活的树突细胞和中性粒细胞的增加,CD8+T细胞,调节性T细胞 (Tregs) 和M2巨细胞的减少.
- 发现,在活跃的UC患者中,枢纽CuDEGs的表达因对生物疗法 (golimumab, vedolizumab, infliximab) 的反应而异.
结论:
- 这项研究强调了与cuproptosis相关的基因在活性UC的病变发生过程中的重要作用.
- 已识别的六个基因签名可以作为活性UC的潜在的cuproptosis相关生物标志物.
- 这些发现为管理活跃UC进展提供了新的治疗目标.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Inflammatory Bowel Disease I: Ulcerative Colitis
192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
138
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
138


